Market revenue in 2023 | USD 51.6 million |
Market revenue in 2030 | USD 77.1 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 53.29% in 2023. Horizon Databook has segmented the Mexico biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is an attractive destination for outsourcing of clinical trials due to lower costs. As people in Mexico cannot afford treatment for chronic diseases, they usually prefer participating in trials. Hence, availability of diverse patient pool is one of the primary drivers.
The establishment of a regulatory entity, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), and shortening of the set up time for clinical trials to 2 months have also attracted many clients. In case of new molecules (biologics), local trials are mandatory for molecules produced in Mexico.
If new molecules are manufactured abroad, COFEPRIS New Molecules Committee may decide whether local trials are required. As part of the efforts to decrease barriers and attract pharmaceutical companies to perform trials locally, COFEPRIS is working on simplifying the administrative process.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into Mexico biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account